Get the Stockscreener App
2.01
1.23%
-0.02
Compugen Ltd stock is traded at $2.01, with a volume of 164.07K.
It is down -1.23% in the last 24 hours and up +30.19% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
See More
Previous Close:
$2.03
Open:
$2.075
24h Volume:
164.07K
Relative Volume:
0.39
Market Cap:
$188.01M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
67.00
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
-8.03%
1M Performance:
+30.19%
6M Performance:
+31.05%
1Y Performance:
-11.28%
1-Day Range:
$1.975
$2.075
1-Week Range:
$1.975
$2.205
52-Week Range:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.01 | 189.88M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen (NASDAQ:CGEN) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Can Compugen Ltd. maintain sales growthHead and Shoulders Patterns & Small Budget Wealth Tips - bollywoodhelpline.com
Aug Opening: Can Fidelis Insurance Holdings Limited stock outperform in a bear marketRate Hike & Stepwise Trade Execution Plans - baoquankhu1.vn
Compugen (NASDAQ:CGEN) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Can Compugen Ltd maintain sales growthEarnings Growth Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Update Recap: Can Compugen Ltd stock continue upward trendPortfolio Value Report & Smart Money Movement Alerts - Bộ Nội Vụ
Targets Report: Will Compugen Ltd stock outperform tech sector in 2025July 2025 Volume & High Win Rate Trade Tips - Bộ Nội Vụ
Compugen shares jump after $65 million royalty monetization deal with AstraZeneca - MSN
Why Compugen Ltd. stock could benefit from AI revolutionRate Cut & Intraday High Probability Alerts - Улправда
Brokers Issue Forecasts for Compugen FY2025 Earnings - Defense World
HC Wainwright Estimates Compugen FY2025 Earnings - MarketBeat
Comparing Compugen (NASDAQ:CGEN) & Psyence Biomedical (NASDAQ:PBM) - Defense World
Compugen (NASDAQ:CGEN) Coverage Initiated at HC Wainwright - Defense World
Compugen rises on royalty deal with AstraZeneca - MSN
How buybacks impact Compugen Ltd. stock valueRate Hike & Capital Efficiency Focused Strategies - Улправда
Why Compugen Ltd. stock could rally in 2025Quarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Will Compugen Ltd. stock benefit from infrastructure spending2025 Dividend Review & Low Volatility Stock Suggestions - Улправда
Compugen (NASDAQ:CGEN) Stock Rating Upgraded by HC Wainwright - MarketBeat
Is Compugen Ltd. stock a bargain at current levelsMoving Average Strategies & Expert-Backed Recommendations That Deliver - Улправда
H.C. Wainwright initiates coverage on Compugen stock with Buy rating By Investing.com - Investing.com Nigeria
Compugen (CGEN): HC Wainwright Initiates Coverage with 'Buy' Rat - GuruFocus
H.C. Wainwright initiates coverage on Compugen stock with Buy rating - Investing.com
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of Compugen (CGEN) with Buy Recommendation - Nasdaq
Operating cash flow per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Will Compugen Ltd. stock benefit from sector rotationWeekly Profit Summary & Daily Growth Stock Tips - Улправда
Is Compugen Ltd. stock a defensive play in 2025Portfolio Gains Summary & Real-Time Volume Analysis Alerts - Улправда
Can Compugen Ltd. stock deliver strong Q4 earningsJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - Улправда
Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Australia
Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca - TipRanks
Compugen (CGEN) Rises on Royalty Deal with AstraZeneca - GuruFocus
Compugen restructures AstraZeneca deal to boost cash coffers - גלובס
Compugen stock soars on $65 million AstraZeneca royalty deal - Investing.com
Compugen Monetizes Portion of Cancer Treatment Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Compugen monetizes portion of cancer drug royalties to AstraZeneca By Investing.com - Investing.com South Africa
Compugen monetizes portion of cancer drug royalties to AstraZeneca - Investing.com
Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca for up to $90 million - marketscreener.com
Compugen Ltd. and Medimmune Limited Enter into Amendment Number 4 to the License Agreement - marketscreener.com
Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million - TradingView — Track All Markets
[6-K] COMPUGEN LTD Current Report (Foreign Issuer) | CGEN SEC FilingForm 6-K - Stock Titan
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan
Revenue per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):